Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trial

Eli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs focused on cancer and autoimmune diseases. It marks Lilly’s fourth partnership with a China drugmaker since the start of 2025, following agreements with Insilico Medicine, Innovent Biologics and Haisco Pharmaceutical Group.

InnoCare did not disclose the specific indications, but the collaboration is expected to explore multiple compounds against a range of disease targets. The sizeable financial commitment underscores Lilly’s strategy to tap Chinese innovation pipelines and expand its global portfolio.

Meanwhile, Immunovant and its majority owner Roivant saw their shares dip after the company announced the termination of its cutaneous lupus erythematosus program. The drug candidate IMVT‑1402 failed to meet its primary endpoints in a proof‑of‑concept trial, prompting the firm to halt further development.

The contrasting news highlights the divergent fortunes in the sector: a major multinational securing a large‑scale deal in China, while a smaller biotech faces a setback in a niche autoimmune indication.